Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02354417 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies
A Phase 1 study, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02354417: Clinical Trial Phase 1 study, sponsored by Fate Therapeutics.
NCT02354417 is a Phase 1 study that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02354417, a Phase 1 study, was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is an open-label, safety study of a single ProHema-CB product administered following myeloablative conditioning regimen in pediatric subjects with hematologic malignancies.
Primary Outcome
To describe the safety profile of ProHema-CB after myeloablative conditioning in pediatric patients with hematologic malignancies. The safety profile will primarily be assessed by neutrophil engraftment.
Interventions
- BIOLOGICAL Biological: ProHema-CB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
Why NCT02354417 stopped before completion
NCT02354417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Biological: ProHema-CB is the first listed.
NCT02354417 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02354417 about?
NCT02354417 is a clinical study titled "A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies". This is an open-label, safety study of a single ProHema-CB product administered following myeloablative conditioning regimen in pediatric subjects with hematologic malignancies.
What is the current status of trial NCT02354417?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-12. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02354417?
The interventions under investigation include: Biological: ProHema-CB (BIOLOGICAL).
Who is sponsoring clinical trial NCT02354417?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02354417's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia